What Breathe Life Sciences does

Breathe Life Sciences (BLS), founded in 2018, is a B2B manufacturer and supplier specializing in botanical pharmaceuticals, unregistered medicines, and consumer health and lifestyle products derived from naturally occurring ingredients including cannabinoids, functional mushrooms, probiotics, collagen, and vitamins. The company operates as a privately held subsidiary of Australian-listed Bioxyne and is headquartered in Rochdale, United Kingdom, with a founder-led management team under CEO Samuel Watson. Its core technical capabilities span bulk cannabinoid ingredient production (isolates and distillates of CBD, CBG, CBN, CBC, CBDV, and THCV), bulk finished product manufacturing (oils, patches, capsules, gummies, balms, and skincare), tailor-made multi-cannabinoid distillates at custom potency ratios, white-label product solutions, and bespoke end-to-end formulation services. Production is anchored in a 15,000 square foot UK facility, supplemented by ISO Class 7 manufacturing in Japan, a GMP-licensed compounding pharmacy in Australia, and a product development and import operation in the Czech Republic, giving the company a vertically integrated, multi-jurisdictional pharmaceutical-grade infrastructure.

The company generates revenue through four primary streams: one-time bulk sales of cannabinoid ingredients and pre-produced CBD products to manufacturers and brands; white-label supply of ready-to-launch branded products; bespoke formulation services billed as professional services engagements; and contract manufacturing for third-party cannabis companies, exemplified by its disclosed partnership with Aurora Cannabis, for whom BLS has produced over 5,000 sublingual oil products and 20,000 vape units across international markets. Pricing is quote-based and not publicly disclosed. The go-to-market is sales-led B2B, targeting cannabis brands, licensed cannabis producers, and consumer health companies seeking access to GMP-certified cannabinoid inputs and finished goods. Customer segments include enterprise licensed producers and a long tail of brand customers utilizing white-label and bespoke services, with pet wellness identified as a secondary use-case vertical.

BLS's competitive positioning rests on its multi-jurisdictional GMP and ISO certifications, in-house formulation expertise staffed by pharmacists, nutritionists, and formulation chemists, and the ability to serve clients across the UK, EU, Japan, and Australia from a single supply relationship. The company does not disclose revenue, funding, or headcount figures beyond a stated 11-50 employee range, and no institutional investment rounds are documented in the available data.

Name

Breathe Life Sciences

Legal name

Breathe Life Sciences

Website

https://breathelifesciences.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Ownership category

akta.pro rank

Product category

Botanical Pharmaceutical & Cannabinoid Manufacturing

NAICS

Medicinal and Botanical Manufacturing (325411), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)

akta.pro primary industry

Hemp & CBD Product Wholesale Distribution (CRAOAIAG)

Keywords

• Cannabinoid ingredient manufacturing
• White label CBD products
• Bespoke formulation services
• Botanical pharmaceutical manufacturing
• Cannabis contract manufacturing

Headquarters

HQ city

Rochdale

HQ country

United Kingdom

HQ region

Europe

Offices5 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Bulk Cannabinoid Ingredients: Pre-produced cannabinoid isolates, distillates, and crude extracts sold in bulk to manufacturers and brands
2. Bulk CBD Products: Pre-produced CBD and cannabinoid products in large volumes including oils, cosmetics, patches, capsules, and gummies
3. White Label Products: Ready-to-launch products with full white labelling services for brand acceleration
4. Bespoke Formulation Services: Custom product creation from formulation through production based on client requirements
5. Contract Manufacturing: Manufacturing products for other cannabis companies including Aurora Cannabis across international markets - over 5,000 sublingual oil products and 20,000 vape units

Pricing tiers

Go-to-market motion1 record

Distribution channels1 record

Marketing channels1 record

Core offering

Breathe Life Sciences researches, develops, and manufactures bulk cannabinoid ingredients (isolates, distillates, crude extracts), pre-produced bulk CBD products, tailor-made distillates with custom cannabinoid ratios, white-label ready-to-launch branded products, and bespoke formulation services for other brands and producers. The company is a B2B supplier specializing in naturally derived ingredients including cannabinoids, functional mushrooms, probiotics, collagen, and vitamins, with GMP and ISO Class 7 manufacturing capabilities across the UK, EU, Japan, and Australia.

Product overview

Breathe Life Sciences is a B2B supplier and manufacturer specializing in medical and health and wellness products, focusing on naturally derived ingredients including cannabinoids, functional mushrooms, probiotics, collagen, and vitamins. The company operates a multi-faceted business model comprising: (1) Bulk Cannabinoid Ingredients (isolates, distillates, and crude extracts of CBD, CBG, CBN, CBC, CBDV, THCV, plus water soluble and full/broad spectrum options), (2) Bulk Product Ingredients (pre-produced finished products in volume), (3) Tailor-Made Distillates (custom ratios of multiple cannabinoids designed to specification), (4) White Label CBD Products (ready-to-launch branded products including oils, balms, lotions, capsules, gummies, and patches), and (5) Bespoke Formulation Services (custom product development from concept through production). The company also manufactures products for third-party brands under contract, as demonstrated by its manufacturing partnership with Aurora Cannabis.

Differentiator

Problem solved

Functional benefit

Products and services

• Bulk Cannabinoid Ingredients Pre-produced cannabinoid isolates, distillates, and crude extracts including CBD Isolate, CBG Isolate, CBN Isolate, CBC Isolate, CBDV Isolate, THCV Isolate, Broad Spectrum Distillate, Full Spectrum Distillate, Water Soluble Cannabinoids, Crude Extracts, and Non Crystalline Crude Extract; sold in bulk to manufacturers and brands.
• Bulk Product Ingredients Pre-produced CBD and cannabinoid products in large volumes including Full Spectrum Oils, Broad Spectrum Oils, Cannabinoid based Cosmetics, Transdermal CBD Patches, CBD Soft Shell Capsules, CBD Hard Shell Capsules, Cannabinoid Infused Gummies, and Pet CBD Oils.
• Tailor-Made Distillates Custom distillates designed using expert knowledge of cannabinoids and terpenes with bespoke cannabinoid ratios, including CBG Distillate (85% CBG), Max Cannabinoid Distillate, CBD/CBG/CBN Distillate, CBN Distillate, and CBG/CBD Distillate variants.
• White Label CBD Products Ready-to-launch products with full white labelling services for brand acceleration, including Full and Broad Spectrum CBD Oils, CBD Isolate Oil, CBG Oil, High Strength Balms, CBD Daily Lotion, Soft Gel Capsules, CBD Gummies, CBD Patches, Pet CBD Oil, and Flavored CBD Distillate.
• Bespoke Formulation Services Custom product creation from scratch, including regulatory and product knowledge as well as production capabilities for custom cannabinoid products covering body care products and topical ointments.
• Contract Manufacturing Manufacturing products for other cannabis companies under contract, including Aurora Cannabis across international markets, producing over 5,000 sublingual oil products and 20,000 vape units.

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature9 records

Partnerships

One partnership is on record.

• Aurora CannabiscoreOEM/ Whitelabel/ Licensing Partner · 9 April 2026Aurora Cannabis has reversed typical supply chain dynamics by outsourcing manufacturing to BLS. BLS manufactures products for Aurora across multiple international markets including over 5,000 sublingual oil products and 20,000 vape units. This represents a significant contract manufacturing partnership for BLS.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• cbdMD: U.S. CBD manufacturer with broad SKU portfolio (oils, gummies, topicals, capsules, pet) and wholesale/white-label channel exposure. Directly comparable on finished product breadth and wholesale go-to-market.
• MediPharm Labs: Canadian-licensed cannabis contract manufacturer producing extracts, distillates, and finished dosage forms for other LPs and brands. Closest comparable to BLS's B2B contract manufacturing and bulk distillate model, with similar GMP-driven service positioning across multiple international markets.
• CV Sciences: Developer and manufacturer of CBD-based products sold wholesale to retailers and as bulk ingredients. Mirrors BLS's split between bulk/raw ingredient supply and finished consumer SKUs.
• Charlotte's Web: Vertically integrated CBD brand offering distillates, isolates, capsules, topicals, and pet products. Comparable in product breadth (oils, capsules, topicals, gummies, pet) and B2B2C distribution model.
• Elixinol Wellness: Global hemp-derived CBD company selling bulk ingredients, white-label, and branded products. Operates similar bulk-ingredient and finished-product distribution across multiple geographies, overlapping with BLS's wholesale and white-label offering.

Others

• Eurofins Scientific: Global contract testing and pharmaceutical support services provider supporting GMP compliance, botanical testing, and cannabinoid characterization. Adjacent rather than competitive — serves the same buyers (cannabis/cannabinoid brands) requiring certified quality and compliance.

Broad incumbents

• Jazz Pharmaceuticals (formerly GW Pharmaceuticals): Pharma company with cannabis-derived drug Epidiolex, operating GMP cannabis manufacturing in the UK. Comparable on pharmaceutical-grade cannabinoid production, regulatory rigor, and UK operational footprint.
• Curaleaf Holdings: One of the largest vertically integrated cannabis operators globally, with cultivation, extraction, manufacturing, and retail. Overlaps with BLS on extracts/manufacturing and serves as both a comparable scale operator and a potential customer for contract manufacturing.
• Tilray Brands: Global cannabis and CPG company with cultivation, GMP-certified manufacturing, and branded medical/wellness products in multiple jurisdictions. Comparable on international GMP footprint and cannabinoid product portfolio breadth.

Emerging players

• CannTrust / CannaRoyalty / PhyeinMed-style contract producers: Emerging cannabis contract manufacturers (e.g., Vivo Cannabis, Botanic Wellness) executing third-party extraction and finished product runs. Comparable in contract manufacturing orientation and emerging regulation compliance.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/breathe-life-sciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Breathe Life Sciences